Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022
February 23, 2022 at 04:05 pm EST
Share
Fulgent Genetics, Inc. provided earning guidance For the first quarter and full year of 2022. For the first quarter of 2022, Total Revenue of approximately $245 million.
For the full year 2022, the company expects total Revenue of approximately $600 million. GAAP income of approximately $6.00 per share.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
FULGENT GENETICS, INC. 
